Mercury Valuation Soars to 52 Billion in 14 Months Defying Fintech Slump Americans Feel Inflations Strain as Holiday Weekend Approaches Travel Recreation and Food Prices Lead Surge Health Ministry Tightens Pregabalin Regulations Under Schedule H1 to Curb Misuse Eli Lilly Reports Positive Phase 3 Results for Obesity Treatment Retatrutide Showcasing Significant Weight Reduction Bloom Energy Shares Surge After 26 Billion FuelCell Deal With AI Data Center Builder Nebius Pokmon Card Market Surges Nostalgia HighProfile Sales and Speculation Drive Collectible Frenzy KFS Q1 2026 Earnings Loss Per Share of 010 Reported Stock Down Slightly CRMD Q1 2026 Earnings Strong EPS Surprise Amidst Limited Revenue Visibility Cosmos Health Inc COSM Q4 2025 Earnings EPS Misses Estimates by Wide Margin UXIN Q1 2025 Earnings Narrowing Loss Reported Stock Edges Lower FITBI Q1 2026 Earnings EPS Surges Past Estimates Modest Stock Response DOW Q1 2026 Earnings EPS Surpasses Estimates Amid Cost Discipline Gibraltar Industries ROCK Holds Steady Near Support Amid Modest Decline Jupiter Neurosciences JUNS Stages a Sharp Rebound from Support Testing Key Resistance Twilio Rides Wave of Optimism Analyzing the Uptrend Above 184 Globa Terra Acquisition Rights GTERR Remain Steady at 011 as Trading Volume Stays Minimal Sempra SRE Holds Steady Near 9155 as Utilities Sector Waits for Catalyst Chevron Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiencies FLR Q1 2026 Earnings EPS Misses Estimates by Wide Margin Stock Edges Higher KAI Q1 2026 Earnings EPS Surges Past Estimates Stock Reacts Positively OPKO Health Q1 2026 Earnings Narrow EPS Beat and Strong Stock Reaction Amid Operational Focus NVMI Q1 2026 Earnings EPS Surpasses Estimates as Profits Rise Northwest Natural Holding Company NWN Q1 2026 Earnings EPS Misses Expectations Amid Operational Challenges Treasury Yield Surge Highlights Bond Market Risks Opens Opportunities in Intermediate and HighYield Sectors Silgan Holdings Q1 2026 Earnings EPS Beats Estimates Amid Focus on Cost Management Royalty Pharma RPRX Edges Higher Testing Resistance Near 57 Amid Steady Gains